论文部分内容阅读
目的:观察疏血通联合依达拉奉治疗急性脑梗死的临床疗效。方法:将120例该病患者随机分为两组,治疗组60例采用疏血通注射液联合依达拉奉注射液治疗,对照组60例采用血栓通联合胞二磷胆碱治疗;在治疗前和治疗后第7天、第14天分别进行ESS和ADL评分,并计算ESS和ADL的增分率,判断临床疗效。结果:治疗组治疗后14天ESS、ADL评分与治疗前比较,差异有统计学意义;与对照组比较,其ESS和ADL的增分率差异也有统计学意义。结论:疏血通联合依达拉奉治疗急性脑梗死有较好疗效。
Objective: To observe the clinical effect of Shuxuetong combined with edaravone in the treatment of acute cerebral infarction. Methods: One hundred and twenty patients were randomly divided into two groups. 60 cases in the treatment group were treated with Shuxuetong injection combined with edaravone injection, and 60 cases in the control group were treated with Xueshuantong combined with citicoline. In the treatment group ESS and ADL scores were measured before and after treatment on the 7th and 14th days respectively. The rates of ESS and ADL were calculated to evaluate the clinical efficacy. Results: The ESS and ADL score of the 14th day after treatment in the treatment group were significantly different from those before treatment, and there were also significant differences in the scores of ESS and ADL between the treatment group and the control group. Conclusion: Shuxuetong combined edaravone has a good effect on acute cerebral infarction.